Holen Sie sich die Stockscreener-App
8.15
6.32%
-0.55
Schlusskurs vom Vortag:
$8.70
Offen:
$8.89
24-Stunden-Volumen:
20,418
Relative Volume:
0.75
Marktkapitalisierung:
$73.09M
Einnahmen:
Nettoeinkommen (Verlust:
$-40.62M
KGV:
-0.4199
EPS:
-19.4076
Netto-Cashflow:
$-35.63M
1W Leistung:
-15.19%
1M Leistung:
-36.72%
6M Leistung:
-31.17%
1J Leistung:
-30.13%
1-Tages-Spanne:
$7.935
$9.64
1-Wochen-Bereich:
$7.935
$9.78
52-Wochen-Spanne:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
8.15 | 73.09M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Promis Neurosciences Inc Stock (PMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-27 | Eingeleitet | Chardan Capital Markets | Buy |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
80,000 stock options go to Ivana Rubino at ProMIS Neurosciences (PMN), exercisable at $9.37. - Stock Titan
Alzheimer’s drug data are expected in Q1 2027. ProMIS hires a former Biogen leader to shape market plans. - Stock Titan
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - Carroll County Mirror-Democrat
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - kalkine.ca
ProMIS Neurosciences Inc. (NASDAQ: PMN) Share Price, PMN Stock News, PMN Share Price & Updates - Kalkine
ProMIS Neurosciences at Moody Capital conference: safety sets it apart By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Nigeria
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com Canada
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com India
ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus By Investing.com - Investing.com UK
ProMIS Neurosciences (PMN) Edges Up 0.24% to $12.56 as Shares Consolidate Between Support and ResistanceChannel Breakout - siam.in
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - Yahoo Finance
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Revenue Estimate Trend - vinanet.vn
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Positive Surprise Momentum - https://www.dars.gov.et/
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Book Value Growth - dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Profit Guidance Range - dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Earnings Forecast Report - www.dars.gov.et
ProMIS (PMN) Results Breakdown: EPS Clears the Reported Estimate in Latest Trading; Trading Response: The Share Price Adds 2.71%Diluted EPS Report - dars.gov.et
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEPS Miss Report - dars.gov.et
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEPS Estimate Trend - dars.gov.et
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - vinanet.vn
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Call Wall - dars.gov.et
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Hedge Fund Favorites - dars.gov.et
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
Promis Neurosciences Q2 Earnings Call Highlights - TradingView
Promis Neurosciences Q2 Earnings Call Highlights - Yahoo Finance
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Promis Neurosciences Inc-Aktie (PMN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kirwin Patrick D. | Director |
Apr 22 '26 |
Buy |
11.33 |
4,000 |
45,320 |
4,653 |
| Williams Eugene | Director |
Mar 05 '26 |
Buy |
24.40 |
2,000 |
48,800 |
12,397 |
| Williams Eugene | Director |
Mar 04 '26 |
Buy |
24.00 |
2,000 |
48,000 |
10,397 |
| Williams Eugene | Director |
Mar 03 '26 |
Buy |
21.89 |
1,000 |
21,890 |
8,397 |
| Williams Eugene | Director |
Mar 02 '26 |
Buy |
22.53 |
1,000 |
22,530 |
7,397 |
| Kaplan Johanne | Chief Development Officer |
Feb 19 '26 |
Buy |
15.35 |
1,629 |
25,005 |
3,941 |
| ABG Management Ltd. | 10% Owner |
Feb 03 '26 |
Buy |
12.13 |
700,741 |
8,499,988 |
943,090 |
| Milbury Max A. | Principal Accounting Officer |
Oct 03 '25 |
Buy |
0.49 |
30,392 |
14,929 |
45,389 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):